X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (34) 34
index medicus (26) 26
female (25) 25
oncology (23) 23
male (22) 22
middle aged (22) 22
aged (17) 17
adult (9) 9
chemotherapy (9) 9
lung neoplasms - drug therapy (8) 8
melanoma (8) 8
respiratory system (8) 8
therapy (8) 8
carcinoma, non-small-cell lung - drug therapy (7) 7
prospective studies (7) 7
cancer (6) 6
medicine & public health (6) 6
prevalence (6) 6
research (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
care and treatment (5) 5
cystic fibrosis (5) 5
dermatology (5) 5
docetaxel (5) 5
lung cancer (5) 5
lung neoplasms - pathology (5) 5
neoplasm staging (5) 5
pulmonary and respiratory medicine (5) 5
surgery (5) 5
vinorelbine (5) 5
aged, 80 and over (4) 4
analysis (4) 4
carcinoma, non-small-cell lung - pathology (4) 4
care (4) 4
combination (4) 4
diagnosis (4) 4
drug therapy (4) 4
early palliative care (4) 4
indoles - adverse effects (4) 4
italy (4) 4
multicenter (4) 4
non-small-cell lung cancer (4) 4
pembrolizumab (4) 4
prognosis (4) 4
simultaneous care (4) 4
sulfonamides - adverse effects (4) 4
vemurafenib (4) 4
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
azithromycin (3) 3
breakthrough pain (3) 3
cancer research (3) 3
carcinoma (3) 3
cisplatin (3) 3
cisplatin - administration & dosage (3) 3
disease progression (3) 3
disease-free survival (3) 3
epirubicin - administration & dosage (3) 3
experience (3) 3
follow-up studies (3) 3
gemcitabine (3) 3
immunotherapy (3) 3
impact (3) 3
italy - epidemiology (3) 3
length of stay (3) 3
management (3) 3
medical oncology (3) 3
medicine (3) 3
medicine, research & experimental (3) 3
melanoma - drug therapy (3) 3
neoplasm metastasis (3) 3
nivolumab (3) 3
opioids (3) 3
original research (3) 3
pain (3) 3
palliative care (3) 3
pharmacology (3) 3
pharmacology & pharmacy (3) 3
pilot projects (3) 3
skin neoplasms - drug therapy (3) 3
supportive care (3) 3
surveys and questionnaires (3) 3
survival analysis (3) 3
treatment outcome (3) 3
trial (3) 3
validation (3) 3
vinblastine - administration & dosage (3) 3
vinblastine - analogs & derivatives (3) 3
adenocarcinoma - drug therapy (2) 2
adenocarcinoma - pathology (2) 2
age (2) 2
aged patients (2) 2
alphapapillomavirus - pathogenicity (2) 2
american society (2) 2
animals (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
association (2) 2
biochemistry & molecular biology (2) 2
braf inhibitors (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 2016, Volume 193, Issue 10, pp. 1123 - 1133
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 10/2019, Volume 30, Issue 9, pp. 969 - 972
Antibodies directed against programmed death receptor 1 emerged as beneficial immune-checkpoint inhibitor therapy in many different types of cancer. However,... 
Medicine, Experimental | Medical research | Research | Drug therapy | Autoimmune diseases | Melanoma
Journal Article
Australasian Journal of Dermatology, ISSN 0004-8380, 08/2019, Volume 60, Issue 3, pp. e242 - e243
Journal Article
Annals of Surgery, ISSN 0003-4932, 07/2007, Volume 246, Issue 1, pp. 77 - 82
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 11/2018, Volume 29, Issue 10, pp. 1026 - 1029
Pembrolizumab is an immune checkpoint inhibitor approved for the treatment of patients with unresectable or metastatic melanoma. Appearance of bone metastases,... 
cutaneous melanoma | pembrolizumab | Bone metastasis | malignant melanoma | osteosclerotic lesions | immunotherapy | melanoma | immune checkpoint inhibitors | osteoblastic response | bone metastasis | PROGNOSTIC-FACTORS | METASTASES | KINASE INHIBITORS | MALIGNANT-MELANOMA | CHEMOTHERAPY | CELL LUNG-CANCER | BREAST-CANCER | FLARE | THERAPY | ONCOLOGY | PHARMACOLOGY & PHARMACY | CARCINOMA
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 09/2019, Volume 79, p. 101887
Small cell lung cancer (SCLC) was defined as a “recalcitrant cancer” because of its dismal prognosis and lack of outcome improvements in the last 30 years.... 
Tumor mutational burden | PD-L1 | SCLC | Checkpoint inhibitors | Pembrolizumab | Atezolizumab | ANTIBODY-DRUG CONJUGATE | CTLA-4 BLOCKADE | ROVALPITUZUMAB TESIRINE | PHASE-III TRIAL | ONCOLOGY | MULTICENTER PHASE-2 | REGULATORY T-CELLS | 2ND-LINE TREATMENT | BRAIN METASTASES | PLUS ETOPOSIDE | 1ST-LINE THERAPY
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 07/2019, Volume 14, Issue 7, pp. e145 - e146
Journal Article
Frontiers in Immunology, ISSN 1664-3224, 11/2016, Volume 7, p. 499
airway infections are a major cause of morbidity and mortality in patients with cystic fibrosis (CF). Azithromycin improves the related clinical outcomes, but... 
Cystic fibrosis | Pseudomonas aeruginosa | Inflammation | Cytokines | Azithromycin | Proteomics | Care and treatment | Bacterial proteins | Analysis | Dosage and administration | Research | Cystic Fibrosis
Journal Article
Journal of Thoracic Disease, ISSN 2072-1439, 01/2018, Volume 10, Issue Suppl 2, pp. S304 - S310
Journal Article
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.